Market capitalization | $143.49m |
Enterprise Value | $178.29m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.38 |
P/S ratio (TTM) P/S ratio | 1.91 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 3.91% |
Revenue (TTM) Revenue | $75.06m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
4 Analysts have issued a OptiNose, Inc. forecast:
4 Analysts have issued a OptiNose, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 75 75 |
4%
4%
|
|
Gross Profit | 67 67 |
7%
7%
|
|
EBITDA | -18 -18 |
50%
50%
|
EBIT (Operating Income) EBIT | -19 -19 |
50%
50%
|
Net Profit | -41 -41 |
12%
12%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.
Head office | United States |
CEO | Ramy Mahmoud |
Employees | 132 |
Founded | 2000 |
Website | www.optinose.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.